Cutler Group LP Viking Therapeutics, Inc. Transaction History

Cutler Group LP

$307 Million
Q1 2024

A detailed history of Cutler Group LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Cutler Group LP holds 350 shares of VKTX stock, worth $14,822. This represents 0.01% of its overall portfolio holdings.

Number of Shares

350

Previous 4,500 92.22%

Holding current value

$14,822

Previous $0 Infinity%

% of portfolio

0.01%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	BUY	$17.4 - $94.5 $6,089 - $33,075	350 New	350 $28,000
Q3 2023 Nov 07, 2023	SELL	$10.92 - $16.0 $24,144 - $35,376	-2,211 Reduced 46.98%	2,495 $27,000
Q2 2023 Jul 18, 2023	BUY	$14.84 - $24.79 $23,907 - $39,936	1,611 Added 52.05%	4,706 $76,000
Q1 2023 May 01, 2023	SELL	$8.08 - $17.33 $16,200 - $34,746	-2,005 Reduced 39.31%	3,095 $51,000
Q4 2022 Feb 07, 2023	SELL	$2.72 - $9.4 $9,068 - $31,339	-3,334 Reduced 39.53%	5,100 $47,000
Q2 2022 Aug 04, 2022	SELL	$2.11 - $3.15 $1,899 - $2,835	-900 Reduced 9.64%	8,434 $24,000
Q1 2022 Apr 14, 2022	BUY	$3.0 - $4.88 $28,002 - $45,549	9,334 New	9,334 $28,000
Q2 2020 Jul 22, 2020	SELL	$4.35 - $8.08 $83,955 - $155,944	-19,300 Closed	0 $0
Q1 2020 May 07, 2020	BUY	$3.45 - $7.95 $49,335 - $113,685	14,300 Added 286.0%	19,300 $90,000
Q4 2019 Feb 06, 2020	SELL	$6.38 - $8.73 $19,140 - $26,190	-3,000 Reduced 37.5%	5,000 $40,000
Q1 2019 May 10, 2019	SELL	$7.58 - $9.94 $31,836 - $41,748	-4,200 Reduced 34.43%	8,000 $79,000
Q4 2018 Feb 05, 2019	SELL	$7.16 - $16.21 $76,826 - $173,933	-10,730 Reduced 46.79%	12,200 $93,000
Q3 2018 Nov 07, 2018	BUY	$9.7 - $19.65 $87,882 - $178,029	9,060 Added 65.32%	22,930 $399,000
Q2 2018 Aug 10, 2018	BUY	$3.88 - $12.74 $53,815 - $176,703	13,870 New	13,870 $131,000

Others Institutions Holding VKTX

# of Institutions

473

Shares Held

65.6M

Call Options Held

5.72M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.25B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account